NZ757213A - Compositions of plinabulin and use thereof - Google Patents

Compositions of plinabulin and use thereof

Info

Publication number
NZ757213A
NZ757213A NZ757213A NZ75721318A NZ757213A NZ 757213 A NZ757213 A NZ 757213A NZ 757213 A NZ757213 A NZ 757213A NZ 75721318 A NZ75721318 A NZ 75721318A NZ 757213 A NZ757213 A NZ 757213A
Authority
NZ
New Zealand
Prior art keywords
combination
plinabulin
immune checkpoint
compositions
checkpoint inhibitors
Prior art date
Application number
NZ757213A
Other languages
English (en)
Inventor
Ramon Mohanlal
Lan Huang
George Lloyd
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Priority to NZ778329A priority Critical patent/NZ778329A/en
Publication of NZ757213A publication Critical patent/NZ757213A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ757213A 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof NZ757213A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ778329A NZ778329A (en) 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470802P 2017-03-13 2017-03-13
US201862621528P 2018-01-24 2018-01-24
PCT/US2018/022064 WO2018169887A1 (en) 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof

Publications (1)

Publication Number Publication Date
NZ757213A true NZ757213A (en) 2022-01-28

Family

ID=63522552

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ757213A NZ757213A (en) 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof
NZ778329A NZ778329A (en) 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ778329A NZ778329A (en) 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof

Country Status (13)

Country Link
US (1) US20200129504A1 (https=)
EP (2) EP3595653B1 (https=)
JP (3) JP7280192B2 (https=)
KR (1) KR102659907B1 (https=)
CN (1) CN110603037A (https=)
AU (2) AU2018236168B2 (https=)
BR (1) BR112019018880A2 (https=)
CA (1) CA3056077A1 (https=)
DK (1) DK3595653T3 (https=)
ES (1) ES2942889T3 (https=)
NZ (2) NZ757213A (https=)
SG (1) SG11201908420WA (https=)
WO (1) WO2018169887A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
GB201713760D0 (en) * 2017-08-28 2017-10-11 Univ Leuven Kath Treatment of epilepsy
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
JP7500438B2 (ja) * 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
GB201913988D0 (en) * 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
EP4045046A4 (en) * 2019-10-15 2024-01-10 Beyondspring Pharmaceuticals Inc. Methods and compositions for treating iron disorders
JP2023524530A (ja) * 2020-05-04 2023-06-12 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
KR102428863B1 (ko) * 2020-08-11 2022-08-03 서울대학교병원 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
MX2024009821A (es) * 2022-02-10 2024-09-18 Beyondspring Pharmaceuticals Inc Formulaciones estables de plinabulina y metodos para su preparacion y uso.
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ES2295695T3 (es) 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2005212399B2 (en) * 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2007035841A1 (en) * 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
CA2926771C (en) * 2013-10-11 2022-07-05 Beyondspring Pharmaceuticals, Inc. Cancer treatment with combination of plinabulin and taxane
CN117100753A (zh) * 2015-02-12 2023-11-24 大连万春布林医药有限公司 普那布林联合免疫检查点抑制剂的用途
KR20180105685A (ko) * 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물

Also Published As

Publication number Publication date
SG11201908420WA (en) 2019-10-30
KR20190122822A (ko) 2019-10-30
ES2942889T3 (es) 2023-06-07
JP2020520889A (ja) 2020-07-16
EP3595653A4 (en) 2020-11-11
KR102659907B1 (ko) 2024-04-24
BR112019018880A2 (pt) 2020-04-14
EP3595653A1 (en) 2020-01-22
JP7280192B2 (ja) 2023-05-23
AU2018236168A1 (en) 2019-10-10
AU2018236168B2 (en) 2024-02-29
NZ778329A (en) 2026-03-27
JP2023099217A (ja) 2023-07-11
JP2025138849A (ja) 2025-09-25
EP3595653B1 (en) 2023-03-08
CA3056077A1 (en) 2018-09-20
WO2018169887A1 (en) 2018-09-20
DK3595653T3 (da) 2023-04-17
US20200129504A1 (en) 2020-04-30
AU2024200709A1 (en) 2024-02-22
CN110603037A (zh) 2019-12-20
EP4190326A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
NZ757213A (en) Compositions of plinabulin and use thereof
ZA202007007B (en) Mcl-1 inhibitors
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
MX2022004259A (es) Inhibidores de mek para el tratamiento de infecciones por hantavirus.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) Compuestos de piridina como inhibidores de shp2 alostericos.
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
PH12019501763A1 (en) Method of reducing neutropenia
MX2018001842A (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
MX2017014253A (es) Metodos y composiciones para promover el crecimiento del cabello.
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
MX2019013862A (es) Terapia de combinacion.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX383944B (es) Composiciones para el cuidado personal.
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2024 BY CPA GLOBAL

Effective date: 20230127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250123